<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00750</drugbank-id>
  <drugbank-id>APRD00180</drugbank-id>
  <name>Prilocaine</name>
  <description>A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)</description>
  <cas-number>721-50-6</cas-number>
  <unii>046O35D44R</unii>
  <average-mass>220.3107</average-mass>
  <monoisotopic-mass>220.157563272</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used as a local anaesthetic and is often used in dentistry.</indication>
  <pharmacodynamics>Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns.</pharmacodynamics>
  <mechanism-of-action>Prilocaine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding>98%</protein-binding>
  <route-of-elimination>Prilocaine is metabolized in both the liver and the kidney and excreted via the kidney.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.</description>
    <direct-parent>Alpha amino acid amides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>Alanine and derivatives</alternative-parent>
    <alternative-parent>Anilides</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Dialkylamines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>N-arylamides</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Toluenes</alternative-parent>
    <substituent>Alanine or derivatives</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Amine</substituent>
    <substituent>Anilide</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-arylamide</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Secondary aliphatic amine</substituent>
    <substituent>Secondary amine</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Toluene</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000962</drugbank-id>
      <name>Prilocaine hydrochloride</name>
      <unii>MJW015BAPH</unii>
      <cas-number>1786-81-8</cas-number>
      <inchikey>BJPJNTKRKALCPP-UHFFFAOYSA-N</inchikey>
      <average-mass>256.77</average-mass>
      <monoisotopic-mass>256.134241</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">2-(Propylamino)-o-propionotoluidide</synonym>
    <synonym language="english" coder="">2-Methyl-alpha-propylaminopropionanilide</synonym>
    <synonym language="english" coder="">alpha-n-Propylamino-2-methylpropionanilide</synonym>
    <synonym language="english" coder="">N-(2-Methylphenyl)-2-(propylamino)propanamide</synonym>
    <synonym language="english" coder="">o-Methyl-2-propylaminopropionanilide</synonym>
    <synonym language="english" coder="">o-Methyl-alpha-propylaminopropionanilide</synonym>
    <synonym language="german" coder="">Prilocain</synonym>
    <synonym language="spanish" coder="inn">Prilocaina</synonym>
    <synonym language="french" coder="inn">Priloca√Øne</synonym>
    <synonym language="english" coder="inn/usan">Prilocaine</synonym>
    <synonym language="english" coder="">Prilocaine base</synonym>
    <synonym language="latin" coder="inn">Prilocainum</synonym>
    <synonym language="english" coder="jan">Propitocaine</synonym>
  </synonyms>
  <products>
    <product>
      <name>4% Citanest Forte Dental With Epinephrine 1:200,000</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347695</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Infiltration</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>4% Citanest Plain Dental</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02435276</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Infiltration</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>AgonEaze</name>
      <labeller>Alvix Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>15455-9528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>AgonEaze</name>
      <labeller>Alvix Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>15455-9528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anodyne LPT</name>
      <labeller>Fortus Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71248-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aprizio Pak</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cadira Compliant Blood Stat</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citanest Forte</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>66312-540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1965-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Submucosal</route>
      <fda-application-number>NDA021383</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citanest Forte DENTAL</name>
      <labeller>Dentsply Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66312-580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Parenteral</route>
      <fda-application-number>ANDA078959</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citanest Plain</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>66312-520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-02</started-marketing-on>
      <ended-marketing-on>2007-03-02</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Dental</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citanest Plain</name>
      <labeller>Dentsply Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66312-630</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1965-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Submucosal</route>
      <fda-application-number>ANDA079235</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dentsply 4% Prilocaine and Epinephrine Injection 1:200,000</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00519227</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1968-12-31</started-marketing-on>
      <ended-marketing-on>2012-07-19</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Infiltration</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dentsply 4% Prilocaine Hydrochloride Dental Injection</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00519235</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2016-06-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Infiltration</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>DermacinRx Cinlone-I CPI</name>
      <labeller>Pure Tek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-351</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intra-articular; Intramuscular</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermacinRx Cinlone-II CPI</name>
      <labeller>Pure Tek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-352</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intra-articular; Intramuscular</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermacinRx Empricaine</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermacinRx Prikaan</name>
      <labeller>Shoreline Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69621-873</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermacinRx Prizopak</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-873</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibucaine HCl 0.5% / Lidocaine 15% / Phenylephrine HCl 1% / Prilocaine 5%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-5071</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dolotranz</name>
      <labeller>Taleos Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>70877-5555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emla</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-29</started-marketing-on>
      <ended-marketing-on>2011-05-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emla</name>
      <labeller>Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)</labeller>
      <ndc-id/>
      <ndc-product-code>76478-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-12</started-marketing-on>
      <ended-marketing-on>2014-03-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emla</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>61874-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-30</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emla</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code>63323-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-29</started-marketing-on>
      <ended-marketing-on>2013-11-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emla</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code>63323-290</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-29</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emla</name>
      <labeller>UNSPECIFIED</labeller>
      <ndc-id/>
      <ndc-product-code>0186-1515</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-27</started-marketing-on>
      <ended-marketing-on>2006-04-27</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emla Cream</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00886858</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Emla Patch</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02057794</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortacin</name>
      <labeller>Plethora Solutions Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002693</ema-product-code>
      <ema-ma-number>EU/1/13/881/001</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Cutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Inflammation Reduction Pack</name>
      <labeller>Tmig, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69176-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074514</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>IV Infusion CPI</name>
      <labeller>Pure Tek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-383</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-15</started-marketing-on>
      <ended-marketing-on>2017-05-23</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leva Set with Occlusive Dressing</name>
      <labeller>Welgo, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70263-222</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-22</started-marketing-on>
      <ended-marketing-on>2016-08-25</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leva Set with Occlusive Dressing</name>
      <labeller>Welgo, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70263-444</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lido Bdk</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lido-Prilo Caine Pack</name>
      <labeller>Tmig, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69176-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine 2.5% and Prilocaine 2.5% Cream</name>
      <labeller>Welgo, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70263-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5194</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-591</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-7058</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on>2014-06-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076320</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-443</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-12</started-marketing-on>
      <ended-marketing-on>2014-03-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-2070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-04</started-marketing-on>
      <ended-marketing-on>2016-01-06</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-25</started-marketing-on>
      <ended-marketing-on>2017-06-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>NuCare Pharamceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076320</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Hi-Tech Pharmacal Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50383-667</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-8955</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076320</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9774</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA205887</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4639</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-577</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1468</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076320</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>E. Fougera &amp; Co. a division of Fougera Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0168-0357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6989</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA205887</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine and Prilocaine Cream</name>
      <labeller>Sola Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70512-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA205887</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidocaine-Prilocaine-Cream Base</name>
      <labeller>Humco Holding Group. Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0395-6110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidopril</name>
      <labeller>Sterling-knight Pharmaceuticals,LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69336-825</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidopril</name>
      <labeller>Sterling-knight Pharmaceuticals,LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69336-821</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-23</started-marketing-on>
      <ended-marketing-on>2016-08-19</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lidopril XR</name>
      <labeller>Sterling-knight Pharmaceuticals,LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69336-826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LiProZonePak</name>
      <labeller>Medarbor Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69665-610</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Livixil Pak</name>
      <labeller>Alvix Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>15455-9504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Livixil Pak</name>
      <labeller>Alvix Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>15455-9504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LP Lite PAK</name>
      <labeller>Alvix Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>15455-9527</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-10</started-marketing-on>
      <ended-marketing-on>2018-03-08</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Medolor Pak Lidocaine and Prilocaine Cream Kit</name>
      <labeller>Medarbor Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69665-828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microvix L</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microvix L</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microvix LP</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-714</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuvakaan</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-706</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oraqix</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>66312-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Periodontal</route>
      <fda-application-number>NDA021451</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oraqix</name>
      <labeller>Dentsply Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02325993</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PainGo KFT</name>
      <labeller>International Brand Management, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69837-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prikaan</name>
      <labeller>Shoreline Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69621-828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prikaan Lite</name>
      <labeller>Shoreline Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69621-810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilo Patch</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-741</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Cutaneous</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilocaine</name>
      <labeller>Letco Medical</labeller>
      <ndc-id/>
      <ndc-product-code>62991-2685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Not applicable</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilocaine HCl 4% Epineph 1:200000inj</name>
      <labeller>Novocol Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00393746</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Infiltration</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Prilocaine Hydrochloride</name>
      <labeller>Septodont</labeller>
      <ndc-id/>
      <ndc-product-code>0362-9014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>ANDA079235</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilocaine Hydrochloride</name>
      <labeller>Letco Medical</labeller>
      <ndc-id/>
      <ndc-product-code>62991-1693</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Not applicable</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilocaine Hydrochloride</name>
      <labeller>Fagron Inc</labeller>
      <ndc-id/>
      <ndc-product-code>51552-0638</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Not applicable</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilocaine Hydrochloride with Epinephrine</name>
      <labeller>Septodont</labeller>
      <ndc-id/>
      <ndc-product-code>0362-9013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>ANDA078959</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilolid</name>
      <labeller>Sterling-knight Pharmaceuticals,LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69336-828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilopentin</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-739</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA204989</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilovix</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PRILOVIX Lite</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-710</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PRILOVIX Lite Plus</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PRILOVIX Plus</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PRILOVIX Plus</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PRILOVIX Plus</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PRILOVIX UltraLite</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-712</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PRILOVIX Ultralite Plus</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-713</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilovixil</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-725</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilovixil</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-725</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prilovixil</name>
      <labeller>Primary Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72275-725</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Priloxx LP External Kit</name>
      <labeller>Sircle Laboratories LLC</labeller>
      <ndc-id/>
      <ndc-product-code>51021-375</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prizotral</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-705</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA019941</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Relador Pak Plus</name>
      <labeller>Accelis Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>69166-155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Relador Pak with Occlusive Dressing</name>
      <labeller>Accelis Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>69166-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA076290</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Venipuncture CPI</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-378</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>ANDA076453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zyvodol</name>
      <labeller>Accumix Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69167-0815</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2015-07-17</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Citanest</name>
      <company>AstraZeneca</company>
    </international-brand>
    <international-brand>
      <name>Prilotekal</name>
      <company>Goldshield</company>
    </international-brand>
    <international-brand>
      <name>Takipril</name>
      <company>Meduna</company>
    </international-brand>
    <international-brand>
      <name>Xylonest</name>
      <company>AstraZeneca</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Fortacin</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilocaine Hydrochloride with Epinephrine</name>
      <ingredients>Epinephrine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilocaine Hydrochloride</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Relador Pak with Occlusive Dressing</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Zyvodol</name>
      <ingredients>Amitriptyline + Diclofenac + Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Relador Pak Plus</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Inflammation Reduction Pack</name>
      <ingredients>Diclofenac + Lidocaine + Prilocaine + Ranitidine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine-Prilocaine-Cream Base</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prikaan</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Cinlone-II CPI</name>
      <ingredients>Lidocaine + Prilocaine + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Prilolid</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Prikaan</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Cinlone-I CPI</name>
      <ingredients>Lidocaine + Prilocaine + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Lidopril</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidopril</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prikaan Lite</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidopril XR</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Leva Set with Occlusive Dressing</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lido-Prilo Caine Pack</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Anodyne LPT</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Citanest Forte</name>
      <ingredients>Epinephrine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine 2.5% and Prilocaine 2.5% Cream</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Leva Set with Occlusive Dressing</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Medolor Pak Lidocaine and Prilocaine Cream Kit</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>LiProZonePak</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PainGo KFT</name>
      <ingredients>Levomenthol + Lidocaine + Methyl salicylate + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Dolotranz</name>
      <ingredients>Lidocaine + Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>IV Infusion CPI</name>
      <ingredients>Lidocaine + Povidone-iodine + Prilocaine + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>LP Lite PAK</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Priloxx LP External Kit</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>AgonEaze</name>
      <ingredients>Lidocaine + Lidocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>AgonEaze</name>
      <ingredients>Lidocaine + Lidocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Citanest Plain</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilovix</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Oraqix</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Cadira Compliant Blood Stat</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lido Bdk</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PRILOVIX Plus</name>
      <ingredients>Lidocaine + Lidocaine + Lidocaine + Prilocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PRILOVIX Plus</name>
      <ingredients>Lidocaine + Lidocaine + Lidocaine + Prilocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PRILOVIX Plus</name>
      <ingredients>Lidocaine + Lidocaine + Lidocaine + Prilocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PRILOVIX Lite</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Aprizio Pak</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Nuvakaan</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Empricaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prizotral</name>
      <ingredients>Lidocaine + Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Prizopak</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilo Patch</name>
      <ingredients>Lidocaine + Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Dibucaine HCl 0.5% / Lidocaine 15% / Phenylephrine HCl 1% / Prilocaine 5%</name>
      <ingredients>Cinchocaine + Lidocaine + Phenylephrine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Livixil Pak</name>
      <ingredients>Lidocaine + Lidocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Livixil Pak</name>
      <ingredients>Lidocaine + Lidocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilocaine</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilocaine Hydrochloride</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilocaine Hydrochloride</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Venipuncture CPI</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PRILOVIX Lite Plus</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PRILOVIX Ultralite Plus</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>PRILOVIX UltraLite</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilopentin</name>
      <ingredients>Gabapentin + Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Citanest Plain</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Citanest Forte DENTAL</name>
      <ingredients>Epinephrine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Lidocaine and Prilocaine Cream</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilovixil</name>
      <ingredients>Lidocaine + Lidocaine + Lidocaine + Prilocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilovixil</name>
      <ingredients>Lidocaine + Lidocaine + Lidocaine + Prilocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilovixil</name>
      <ingredients>Lidocaine + Lidocaine + Lidocaine + Prilocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Microvix LP</name>
      <ingredients>Benzalkonium + Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Microvix L</name>
      <ingredients>Benzalkonium + Lidocaine + Lidocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Microvix L</name>
      <ingredients>Benzalkonium + Lidocaine + Lidocaine + Prilocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Oraqix</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>4% Citanest Forte Dental With Epinephrine 1:200,000</name>
      <ingredients>Epinephrine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Dentsply 4% Prilocaine and Epinephrine Injection 1:200,000</name>
      <ingredients>Epinephrine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>4% Citanest Plain Dental</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Dentsply 4% Prilocaine Hydrochloride Dental Injection</name>
      <ingredients>Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla Cream</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Emla Patch</name>
      <ingredients>Lidocaine + Prilocaine</ingredients>
    </mixture>
    <mixture>
      <name>Prilocaine HCl 4% Epineph 1:200000inj</name>
      <ingredients>Epinephrine + Prilocaine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>APP Pharmaceuticals</name>
      <url>http://www.apppharma.com</url>
    </packager>
    <packager>
      <name>Astra Pharma Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>AstraZeneca Inc.</name>
      <url>http://www.astrazeneca.ca</url>
    </packager>
    <packager>
      <name>DENTSPLY International</name>
      <url>http://www.dentsply.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>E. Fougera and Co.</name>
      <url>http://www.fougera.com</url>
    </packager>
    <packager>
      <name>Hi Tech Pharmacal Co. Inc.</name>
      <url>http://www.hitechpharm.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Nycomed Inc.</name>
      <url>http://www.nycomed.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Preferred Pharmaceuticals Inc.</name>
      <url>http://www.preferredpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Recipharm AB</name>
      <url>http://www.recipharm.com</url>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Tolmar Inc.</name>
      <url>http://www.tolmar.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Prilocaine hcl powder</description>
      <cost currency="USD">3.98</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amide Local Anesthetic</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Anesthetics</category>
      <mesh-id>D000777</mesh-id>
    </category>
    <category>
      <category>Anesthetics, Local</category>
      <mesh-id>D000779</mesh-id>
    </category>
    <category>
      <category>Anilides</category>
      <mesh-id>D000813</mesh-id>
    </category>
    <category>
      <category>Aniline Compounds</category>
      <mesh-id>D000814</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Local Anesthesia</category>
      <mesh-id>D000772</mesh-id>
    </category>
    <category>
      <category>Methemoglobinemia Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Sensory System Agents</category>
      <mesh-id>D018689</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Infiltration</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Infiltration</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Submucosal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Dental</route>
      <strength>40 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Submucosal</route>
      <strength>40 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intra-articular; Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Cutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Periodontal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Cutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Not applicable</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>40 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form/>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N01BB54">
      <level code="N01BB">Amides</level>
      <level code="N01B">ANESTHETICS, LOCAL</level>
      <level code="N01">ANESTHETICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
    <atc-code code="N01BB04">
      <level code="N01BB">Amides</level>
      <level code="N01B">ANESTHETICS, LOCAL</level>
      <level code="N01">ANESTHETICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>72:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00750.pdf?1265922746</msds>
  <patents>
    <patent>
      <number>6031007</number>
      <country>United States</country>
      <approved>2000-02-29</approved>
      <expires>2017-04-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The risk or severity of methemoglobinemia can be increased when Butalbital is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The risk or severity of methemoglobinemia can be increased when Phenytoin is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>The risk or severity of methemoglobinemia can be increased when Nitroprusside is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Sulfadiazine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Nitric Oxide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Quinine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of methemoglobinemia can be increased when Celecoxib is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Chloroquine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>The risk or severity of methemoglobinemia can be increased when Nitrofurantoin is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide dinitrate</name>
      <description>The risk or severity of methemoglobinemia can be increased when Isosorbide dinitrate is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>The risk or severity of methemoglobinemia can be increased when Isosorbide mononitrate is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01086</drugbank-id>
      <name>Benzocaine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Benzocaine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Primaquine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The risk or severity of methemoglobinemia can be increased when Phenobarbital is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The risk or severity of methemoglobinemia can be increased when Zopiclone is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Antipyrine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Phenazopyridine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>The risk or severity of methemoglobinemia can be increased when Amyl Nitrite is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06706</drugbank-id>
      <name>Isometheptene</name>
      <description>The risk or severity of methemoglobinemia can be increased when Isometheptene is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06795</drugbank-id>
      <name>Mafenide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Mafenide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Nitrous oxide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Ifosfamide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Sulfasalazine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00259</drugbank-id>
      <name>Sulfanilamide</name>
      <description>The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00891</drugbank-id>
      <name>Sulfapyridine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Sulfapyridine is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>Hyaluronidase (ovine) can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09266</drugbank-id>
      <name>Technetium Tc-99m tilmanocept</name>
      <description>Prilocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.87</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.26e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N-(2-methylphenyl)-2-(propylamino)propanamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>prilocaine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>220.3107</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>220.157563272</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCNC(C)C(=O)NC1=CC=CC=C1C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C13H20N2O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>MVFGUOIZUNYYSO-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>41.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>67.86</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>25.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.82</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>541 mg/L</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>37-38 ¬∞C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>159-162 ¬∞C at 1.00E-01 mm Hg</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.11</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>5776</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9797</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>8404</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>4906</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505066</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07531</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00553</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4737</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50225477</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA451101</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000511</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Prilocaine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1194</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000401</smpdb-id>
      <name>Prilocaine Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00368</drugbank-id>
          <name>Norepinephrine</name>
        </drug>
        <drug>
          <drugbank-id>DB00750</drugbank-id>
          <name>Prilocaine</name>
        </drug>
        <drug>
          <drugbank-id>DB00988</drugbank-id>
          <name>Dopamine</name>
        </drug>
        <drug>
          <drugbank-id>DB01345</drugbank-id>
          <name>Potassium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>Q9Y5Y9</uniprot-id>
        <uniprot-id>Q07699</uniprot-id>
        <uniprot-id>P17787</uniprot-id>
        <uniprot-id>P43681</uniprot-id>
        <uniprot-id>O00555</uniprot-id>
        <uniprot-id>Q02641</uniprot-id>
        <uniprot-id>Q9NY47</uniprot-id>
        <uniprot-id>Q9NZV8</uniprot-id>
        <uniprot-id>Q9NS61</uniprot-id>
        <uniprot-id>P05023</uniprot-id>
        <uniprot-id>P50993</uniprot-id>
        <uniprot-id>P13637</uniprot-id>
        <uniprot-id>Q13733</uniprot-id>
        <uniprot-id>P05026</uniprot-id>
        <uniprot-id>P14415</uniprot-id>
        <uniprot-id>P54709</uniprot-id>
        <uniprot-id>B7ZKV8</uniprot-id>
        <uniprot-id>P54710</uniprot-id>
        <uniprot-id>P01189</uniprot-id>
        <uniprot-id>P01203</uniprot-id>
        <uniprot-id>P16519</uniprot-id>
        <uniprot-id>Q05586</uniprot-id>
        <uniprot-id>Q12879</uniprot-id>
        <uniprot-id>Q8TCU5</uniprot-id>
        <uniprot-id>P35348</uniprot-id>
        <uniprot-id>P08908</uniprot-id>
        <uniprot-id>P23975</uniprot-id>
        <uniprot-id>P31645</uniprot-id>
        <uniprot-id>Q01959</uniprot-id>
        <uniprot-id>P21728</uniprot-id>
        <uniprot-id>P35372</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000197</id>
      <name>Sodium channel protein type 5 subunit alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q14524" source="Swiss-Prot">
        <name>Sodium channel protein type 5 subunit alpha</name>
        <general-function>Voltage-gated sodium channel activity involved in sa node cell action potential</general-function>
        <specific-function>This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is responsible for the initial upstroke of the action potential. Channel inactivation is regulated by intracellular calcium levels.</specific-function>
        <gene-name>SCN5A</gene-name>
        <locus>3p21</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>127-150
159-178
192-210
217-236
253-276
390-415
712-736
748-771
780-799
806-825
842-862
914-939
1201-1224
1238-1263
1270-1291
1296-1317
1337-1359
1444-1470
1524-1547
1559-1582
1589-1612
1623-1644
1660-1682
1748-1772</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.23</theoretical-pi>
        <molecular-weight>226937.475</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SCN5A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M77235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>184039</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14524</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SCN5A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>HH1</synonym>
          <synonym>Sodium channel protein cardiac muscle subunit alpha</synonym>
          <synonym>Sodium channel protein type V subunit alpha</synonym>
          <synonym>Voltage-gated sodium channel subunit alpha Nav1.5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036969|Sodium channel protein type 5 subunit alpha
MANFLLPRGTSSFRRFTRESLAAIEKRMAEKQARGSTTLQESREGLPEEEAPRPQLDLQA
SKKLPDLYGNPPQELIGEPLEDLDPFYSTQKTFIVLNKGKTIFRFSATNALYVLSPFHPI
RRAAVKILVHSLFNMLIMCTILTNCVFMAQHDPPPWTKYVEYTFTAIYTFESLVKILARG
FCLHAFTFLRDPWNWLDFSVIIMAYTTEFVDLGNVSALRTFRVLRALKTISVISGLKTIV
GALIQSVKKLADVMVLTVFCLSVFALIGLQLFMGNLRHKCVRNFTALNGTNGSVEADGLV
WESLDLYLSDPENYLLKNGTSDVLLCGNSSDAGTCPEGYRCLKAGENPDHGYTSFDSFAW
AFLALFRLMTQDCWERLYQQTLRSAGKIYMIFFMLVIFLGSFYLVNLILAVVAMAYEEQN
QATIAETEEKEKRFQEAMEMLKKEHEALTIRGVDTVSRSSLEMSPLAPVNSHERRSKRRK
RMSSGTEECGEDRLPKSDSEDGPRAMNHLSLTRGLSRTSMKPRSSRGSIFTFRRRDLGSE
ADFADDENSTAGESESHHTSLLVPWPLRRTSAQGQPSPGTSAPGHALHGKKNSTVDCNGV
VSLLGAGDPEATSPGSHLLRPVMLEHPPDTTTPSEEPGGPQMLTSQAPCVDGFEEPGARQ
RALSAVSVLTSALEELEESRHKCPPCWNRLAQRYLIWECCPLWMSIKQGVKLVVMDPFTD
LTITMCIVLNTLFMALEHYNMTSEFEEMLQVGNLVFTGIFTAEMTFKIIALDPYYYFQQG
WNIFDSIIVILSLMELGLSRMSNLSVLRSFRLLRVFKLAKSWPTLNTLIKIIGNSVGALG
NLTLVLAIIVFIFAVVGMQLFGKNYSELRDSDSGLLPRWHMMDFFHAFLIIFRILCGEWI
ETMWDCMEVSGQSLCLLVFLLVMVIGNLVVLNLFLALLLSSFSADNLTAPDEDREMNNLQ
LALARIQRGLRFVKRTTWDFCCGLLRQRPQKPAALAAQGQLPSCIATPYSPPPPETEKVP
PTRKETRFEEGEQPGQGTPGDPEPVCVPIAVAESDTDDQEEDEENSLGTEEESSKQQESQ
PVSGGPEAPPDSRTWSQVSATASSEAEASASQADWRQQWKAEPQAPGCGETPEDSCSEGS
TADMTNTAELLEQIPDLGQDVKDPEDCFTEGCVRRCPCCAVDTTQAPGKVWWRLRKTCYH
IVEHSWFETFIIFMILLSSGALAFEDIYLEERKTIKVLLEYADKMFTYVFVLEMLLKWVA
YGFKKYFTNAWCWLDFLIVDVSLVSLVANTLGFAEMGPIKSLRTLRALRPLRALSRFEGM
RVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFGRCINQTEGDLPLNYTIVNN
KSQCESLNLTGELYWTKVKVNFDNVGAGYLALLQVATFKGWMDIMYAAVDSRGYEEQPQW
EYNLYMYIYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKK
LGSKKPQKPIPRPLNKYQGFIFDIVTKQAFDVTIMFLICLNMVTMMVETDDQSPEKINIL
AKINLLFVAIFTGECIVKLAALRHYYFTNSWNIFDFVVVILSIVGTVLSDIIQKYFFSPT
LFRVIRLARIGRILRLIRGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMANFA
YVKWEAGIDDMFNFQTFANSMLCLFQITTSAGWDGLLSPILNTGPPYCDPTLPNSNGSRG
DCGSPAVGILFFTTYIIISFLIVVNMYIAIILENFSVATEESTEPLSEDDFDMFYEIWEK
FDPEATQFIEYSVLSDFADALSEPLRIAKPNQISLINMDLPMVSGDRIHCMDILFAFTKR
VLGESGEMDALKIQMEEKFMAANPSKISYEPITTTLRRKHEEVSAMVIQRAFRRHLLQRS
LKHASFLFRQQAGSGLSEEDAPEREGLIAYVMSENFSRPLGPPSSSSISSTSFPPSYDSV
TRATSDNLQVRGSDYSHSEDLADFPPSPDRDRESIV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009999|Sodium channel protein type 5 subunit alpha (SCN5A)
ATGGCAAACTTCCTATTACCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCC
CTGGCAGCCATCGAGAAGCGCATGGCAGAGAAGCAAGCCCGCGGCTCAACCACCTTGCAG
GAGAGCCGAGAGGGGCTGCCCGAGGAGGAGGCTCCCCGGCCCCAGCTGGACCTGCAGGCC
TCCAAAAAGCTGCCAGATCTCTATGGCAATCCACCCCAAGAGCTCATCGGAGAGCCCCTG
GAGGACCTGGACCCCTTCTATAGCACCCAAAAGACTTTCATCGTACTGAATAAAGGCAAG
ACCATCTTCCGGTTCAGTGCCACCAACGCCTTGTATGTCCTCAGTCCCTTCCACCCCATC
CGGAGAGCGGCTGTGAAGATTCTGGTTCACTCGCTCTTCAACATGCTCATCATGTGCACC
ATCCTCACCAACTGCGTGTTCATGGCCCAGCACGACCCTCCACCCTGGACCAAGTATGTC
GAGTACACCTTCACCGCCATTTACACCTTTGAGTCTCTGGTCAAGATTCTGGCTCGAGGC
TTCTGCCTGCACGCGTTCACTTTCCTTCGGGACCCATGGAACTGGCTGGACTTTAGTGTG
ATTATCATGGCATACACAACTGAATTTGTGGACCTGGGCAATGTCTCAGCCTTACGCACC
TTCCGAGTCCTCCGGGCCCTGAAAACTATATCAGTCATTTCAGGGCTGAAGACCATCGTG
GGGGCCCTGATCCAGTCTGTGAAGAAGCTGGCTGATGTGATGGTCCTCACAGTCTTCTGC
CTCAGCGTCTTTGCCCTCATCGGCCTGCAGCTCTTCATGGGCAACCTAAGGCACAAGTGC
GTGCGCAACTTCACAGCGCTCAACGGCACCAACGGCTCCGTGGAGGCCGACGGCTTGGTC
TGGGAATCCCTGGACCTTTACCTCAGTGATCCAGAAAATTACCTGCTCAAGAACGGCACC
TCTGATGTGTTACTGTGTGGGAACAGCTCTGACGCTGGGACATGTCCGGAGGGCTACCGG
TGCCTAAAGGCAGGCGAGAACCCCGACCACGGCTACACCAGCTTCGATTCCTTTGCCTGG
GCCTTTCTTGCACTCTTCCGCCTGATGACGCAGGACTGCTGGGAGCGCCTCTATCAGCAG
ACCCTCAGGTCCGCAGGGAAGATCTACATGATCTTCTTCATGCTTGTCATCTTCCTGGGG
TCCTTCTACCTGGTGAACCTGATCCTGGCCGTGGTCGCAATGGCCTATGAGGAGCAAAAC
CAAGCCACCATCGCTGAGACCGAGGAGAAGGAAAAGCGCTTCCAGGAGGCCATGGAAATG
CTCAAGAAAGAACACGAGGCCCTCACCATCAGGGGTGTGGATACCGTGTCCCGTAGCTCC
TTGGAGATGTCCCCTTTGGCCCCAGTAAACAGCCATGAGAGAAGAAGCAAGAGGAGAAAA
CGGATGTCTTCAGGAACTGAGGAGTGTGGGGAGGACAGGCTCCCCAAGTCTGACTCAGAA
GATGGTCCCAGAGCAATGAATCATCTCAGCCTCACCCGTGGCCTCAGCAGGACTTCTATG
AAGCCACGTTCCAGCCGCGGGAGCATTTTCACCTTTCGCAGGCGAGACCTGGGTTCTGAA
GCAGATTTTGCAGATGATGAAAACAGCACAGCGGGGGAGAGCGAGAGCCACCACACATCA
CTGCTGGTGCCCTGGCCCCTGCGCCGGACCAGTGCCCAGGGACAGCCCAGTCCCGGAACC
TCGGCTCCTGGCCACGCCCTCCATGGCAAAAAGAACAGCACTGTGGACTGCAATGGGGTG
GTCTCATTACTGGGGGCAGGCGACCCAGAGGCCACATCCCCAGGAAGCCACCTCCTCCGC
CCTGTGATGCTAGAGCACCCGCCAGACACGACCACGCCATCGGAGGAGCCAGGCGGGCCC
CAGATGCTGACCTCCCAGGCTCCGTGTGTAGATGGCTTCGAGGAGCCAGGAGCACGGCAG
CGGGCCCTCAGCGCAGTCAGCGTCCTCACCAGCGCACTGGAAGAGTTAGAGGAGTCTCGC
CACAAGTGTCCACCATGCTGGAACCGTCTCGCCCAGCGCTACCTGATCTGGGAGTGCTGC
CCGCTGTGGATGTCCATCAAGCAGGGAGTGAAGTTGGTGGTCATGGACCCGTTTACTGAC
CTCACCATCACTATGTGCATCGTACTCAACACACTCTTCATGGCGCTGGAGCACTACAAC
ATGACAAGTGAATTCGAGGAGATGCTGCAGGTCGGAAACCTGGTCTTCACAGGGATTTTC
ACAGCAGAGATGACCTTCAAGATCATTGCCCTCGACCCCTACTACTACTTCCAACAGGGC
TGGAACATCTTCGACAGCATCATCGTCATCCTTAGCCTCATGGAGCTGGGCCTGTCCCGC
ATGAGCAACTTGTCGGTGCTGCGCTCCTTCCGCCTGCTGCGGGTCTTCAAGCTGGCCAAA
TCATGGCCCACCCTGAACACACTCATCAAGATCATCGGGAACTCAGTGGGGGCACTGGGG
AACCTGACACTGGTGCTAGCCATCATCGTGTTCATCTTTGCTGTGGTGGGCATGCAGCTC
TTTGGCAAGAACTACTCGGAGCTGAGGGACAGCGACTCAGGCCTGCTGCCTCGCTGGCAC
ATGATGGACTTCTTTCATGCCTTCCTCATCATCTTCCGCATCCTCTGTGGAGAGTGGATC
GAGACCATGTGGGACTGCATGGAGGTGTCGGGGCAGTCATTATGCCTGCTGGTCTTCTTG
CTTGTTATGGTCATTGGCAACCTTGTGGTCCTGAATCTCTTCCTGGCCTTGCTGCTCAGC
TCCTTCAGTGCAGACAACCTCACAGCCCCTGATGAGGACAGAGAGATGAACAACCTCCAG
CTGGCCCTGGCCCGCATCCAGAGGGGCCTGCGCTTTGTCAAGCGGACCACCTGGGATTTC
TGCTGTGGTCTCCTGCGGCAGCGGCCTCAGAAGCCCGCAGCCCTTGCCGCCCAGGGCCAG
CTGCCCAGCTGCATTGCCACCCCCTACTCCCCGCCACCCCCAGAGACGGAGAAGGTGCCT
CCCACCCGCAAGGAAACACGGTTTGAGGAAGGCGAGCAACCAGGCCAGGGCACCCCCGGG
GATCCAGAGCCCGTGTGTGTGCCCATCGCTGTGGCCGAGTCAGACACAGATGACCAAGAA
GAAGATGAGGAGAACAGCCTGGGCACGGAGGAGGAGTCCAGCAAGCAGGAATCCCAGCCT
GTGTCCGGTGGCCCAGAGGCCCCTCCGGATTCCAGGACCTGGAGCCAGGTGTCAGCGACT
GCCTCCTCTGAGGCCGAGGCCAGTGCATCTCAGGCCGACTGGCGGCAGCAGTGGAAAGCG
GAACCCCAGGCCCCAGGGTGCGGTGAGACCCCAGAGGACAGTTGCTCCGAGGGCAGCACA
GCAGACATGACCAACACCGCTGAGCTCCTGGAGCAGATCCCTGACCTCGGCCAGGATGTC
AAGGACCCAGAGGACTGCTTCACTGAAGGCTGTGTCCGGCGCTGTCCCTGCTGTGCGGTG
GACACCACACAGGCCCCAGGGAAGGTCTGGTGGCGGTTGCGCAAGACCTGCTACCACATC
GTGGAGCACAGCTGGTTCGAGACATTCATCATCTTCATGATCCTACTCAGCAGTGGAGCG
CTGGCCTTCGAGGACATCTACCTAGAGGAGCGGAAGACCATCAAGGTTCTGCTTGAGTAT
GCCGACAAGATGTTCACATATGTCTTCGTGCTGGAGATGCTGCTCAAGTGGGTGGCCTAC
GGCTTCAAGAAGTACTTCACCAATGCCTGGTGCTGGCTCGACTTCCTCATCGTAGACGTC
TCTCTGGTCAGCCTGGTGGCCAACACCCTGGGCTTTGCCGAGATGGGCCCCATCAAGTCA
CTGCGGACGCTGCGTGCACTCCGTCCTCTGAGAGCTCTGTCACGATTTGAGGGCATGAGG
GTGGTGGTCAATGCCCTGGTGGGCGCCATCCCGTCCATCATGAACGTCCTCCTCGTCTGC
CTCATCTTCTGGCTCATCTTCAGCATCATGGGCGTGAACCTCTTTGCGGGGAAGTTTGGG
AGGTGCATCAACCAGACAGAGGGAGACTTGCCTTTGAACTACACCATCGTGAACAACAAG
AGCCAGTGTGAGTCCTTGAACTTGACCGGAGAATTGTACTGGACCAAGGTGAAAGTCAAC
TTTGACAACGTGGGGGCCGGGTACCTGGCCCTTCTGCAGGTGGCAACATTTAAAGGCTGG
ATGGACATTATGTATGCAGCTGTGGACTCCAGGGGGTATGAAGAGCAGCCTCAGTGGGAA
TACAACCTCTACATGTACATCTATTTTGTCATTTTCATCATCTTTGGGTCTTTCTTCACC
CTGAACCTCTTTATTGGTGTCATCATTGACAACTTCAACCAACAGAAGAAAAAGTTAGGG
GGCCAGGACATCTTCATGACAGAGGAGCAGAAGAAGTACTACAATGCCATGAAGAAGCTG
GGCTCCAAGAAGCCCCAGAAGCCCATCCCACGGCCCCTGAACAAGTACCAGGGCTTCATA
TTCGACATTGTGACCAAGCAGGCCTTTGACGTCACCATCATGTTTCTGATCTGCTTGAAT
ATGGTGACCATGATGGTGGAGACAGATGACCAAAGTCCTGAGAAAATCAACATCTTGGCC
AAGATCAACCTGCTCTTTGTGGCCATCTTCACAGGCGAGTGTATTGTCAAGCTGGCTGCC
CTGCGCCACTACTACTTCACCAACAGCTGGAATATCTTCGACTTCGTGGTTGTCATCCTC
TCCATCGTGGGCACTGTGCTCTCGGACATCATCCAGAAGTACTTCTTCTCCCCGACGCTC
TTCCGAGTCATCCGCCTGGCCCGAATAGGCCGCATCCTCAGACTGATCCGAGGGGCCAAG
GGGATCCGCACGCTGCTCTTTGCCCTCATGATGTCCCTGCCTGCCCTCTTCAACATCGGG
CTGCTGCTCTTCCTCGTCATGTTCATCTACTCCATCTTTGGCATGGCCAACTTCGCTTAT
GTCAAGTGGGAGGCTGGCATCGACGACATGTTCAACTTCCAGACCTTCGCCAACAGCATG
CTGTGCCTCTTCCAGATCACCACGTCGGCCGGCTGGGATGGCCTCCTCAGCCCCATCCTC
AACACTGGGCCGCCCTACTGCGACCCCACTCTGCCCAACAGCAATGGCTCTCGGGGGGAC
TGCGGGAGCCCAGCCGTGGGCATCCTCTTCTTCACCACCTACATCATCATCTCCTTCCTC
ATCGTGGTCAACATGTACATTGCCATCATCCTGGAGAACTTCAGCGTGGCCACGGAGGAG
AGCACCGAGCCCCTGAGTGAGGACGACTTCGATATGTTCTATGAGATCTGGGAGAAATTT
GACCCAGAGGCCACTCAGTTTATTGAGTATTCGGTCCTGTCTGACTTTGCCGATGCCCTG
TCTGAGCCACTCCGTATCGCCAAGCCCAACCAGATAAGCCTCATCAACATGGACCTGCCC
ATGGTGAGTGGGGACCGCATCCATTGCATGGACATTCTCTTTGCCTTCACCAAAAGGGTC
CTGGGGGAGTCTGGGGAGATGGACGCCCTGAAGATCCAGATGGAGGAGAAGTTCATGGCA
GCCAACCCATCCAAGATCTCCTACGAGCCCATCACCACCACACTCCGGCGCAAGCACGAA
GAGGTGTCGGCCATGGTTATCCAGAGAGCCTTCCGCAGGCACCTGCTGCAACGCTCTTTG
AAGCATGCCTCCTTCCTCTTCCGTCAGCAGGCGGGCAGCGGCCTCTCCGAAGAGGATGCC
CCTGAGCGAGAGGGCCTCATCGCCTACGTGATGAGTGAGAACTTCTCCCGACCCCTTGGC
CCACCCTCCAGCTCCTCCATCTCCTCCACTTCCTTCCCACCCTCCTATGACAGTGTCACT
AGAGCCACCAGCGATAACCTCCAGGTGCGGGGGTCTGACTACAGCCACAGTGAAGATCTC
GCCGACTTCCCCCCTTCTCCGGACAGGGACCGTGAGTCCATCGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF06512</identifier>
            <name>Na_trans_assoc</name>
          </pfam>
          <pfam>
            <identifier>PF11933</identifier>
            <name>Na_trans_cytopl</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercalated disc</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T-tubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated sodium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Z disc</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ankyrin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fibroblast growth factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nitric-oxide synthase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein domain specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated sodium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated sodium channel activity involved in AV node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated sodium channel activity involved in bundle of His cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated sodium channel activity involved in cardiac muscle cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated sodium channel activity involved in Purkinje myocyte action potential</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated sodium channel activity involved in SA node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>AV node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>AV node cell to bundle of His cell communication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brainstem development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bundle of His cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle cell action potential involved in contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac ventricle development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebellum development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during AV node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during bundle of His cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during cardiac muscle cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during Purkinje myocyte cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during SA node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuronal action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>odontogenesis of dentin-containing tooth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of atrial cardiac muscle cell membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of atrial cardiac muscle cell membrane repolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle cell contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate by cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ventricular cardiac muscle cell membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ventricular cardiac muscle cell membrane repolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to denervation involved in regulation of muscle adaptation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>SA node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telencephalon development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventricular cardiac muscle cell action potential</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>